CKDXF.US Opthea Ltd

Healthcare Biotechnology USA Stocks
0.0107 USD
Close of Nov 13, 2026
0.0100 0.4400
Market cap
USD 14.6M
P/E
0.1x
P/B
0.72x
ROE
1,076.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is CKDXF.US undervalued?

Graham number

The Graham number of Opthea Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Opthea Ltd fundamental analysis

No fundamental analysis for Opthea Ltd yet.

Opthea Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Opthea Ltd

Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was i…

Full company profile